Strategic Partnerships Position Eureka as a preferred partner for co-development or licensing of fully-human antibodies against intracellular cancer antigens, leveraging Memorial Sloan Kettering collaboration and the Novartis program to attract pharma and academic collaborators for preclinical assets.

Manufacturing Collaborations Leverage CDMO partnerships and ATMP manufacturing capabilities to offer joint manufacturing, process development, or tech-transfer opportunities for Eureka’s T-cell therapies and antibody platforms to CROs and sponsors preparing for clinical trials.

AI-Driven Discovery Capitalize on the AI-powered antibody discovery model with Great Bay Bio to pitch platform licenses or joint development deals with biotech firms seeking accelerated discovery and candidate generation.

Licensing Opportunities Use the NCI licensing agreement for a mesothelin-targeting antibody as evidence of licensing potential to secure multi-target collaborations with large pharma interested in ARTEMIS TCR-based therapies.

Funding and Milestones Highlight government and grant support to design milestone-based partnerships that share risk, fund pediatric liver cancer programs, and de-risk upfront investments for potential partners.